Toxicity – stomatitis · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – diarrhoea · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Quality of life · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Progression‐free survival · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 1.07 [0.91, 1.25]
398 participants
High
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.27 [1.02, 1.58]
1885 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found